Analyzing Roivant Sciences (ROIV) & Its Competitors

Roivant Sciences (NASDAQ:ROIV) is one of 846 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Roivant Sciences to similar businesses based on the strength of its risk, dividends, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Profitability

This table compares Roivant Sciences and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-838.21%	-22.03%	-20.55%
Roivant Sciences Competitors	-12,285.98%	-196.04%	-30.61%

Risk & Volatility

Roivant Sciences has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Roivant Sciences’ rivals have a beta of 1.15, suggesting that their average share price is 15% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Roivant Sciences and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1	2	10	1	2.79
Roivant Sciences Competitors	9905	15274	45596	1595	2.54

Roivant Sciences currently has a consensus price target of $46.64, indicating a potential upside of 13.22%. As a group, “Biotechnology” companies have a potential upside of 99.56%. Given Roivant Sciences’ rivals higher probable upside, analysts clearly believe Roivant Sciences has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 47.7% of shares of all “Biotechnology” companies are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Roivant Sciences and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Roivant Sciences	$8.26 million	-$299.77 million	-77.72
Roivant Sciences Competitors	$729.47 million	$11.46 million	-14.85

Roivant Sciences’ rivals have higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Roivant Sciences beats its rivals on 8 of the 12 factors compared.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.